Severe streptococcal cellulitis after subcutaneous pegylated interferon alfa-2B in a diabetic patient.
Lanternier
Fanny
F
Bon
Cyriaque
C
Memain
Nathalie
N
Roulot
Dominique
D
Lortholary
Olivier
O
D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D002481:Cellulitis / Q000382:microbiology* / Q000628:therapy; D003920:Diabetes Mellitus; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007279:Injections, Subcutaneous / Q000009:adverse effects; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D013290:Streptococcal Infections / Q000150:complications* / Q000209:etiology / Q000628:therapy; D000637:Transaminases / Q000097:blood
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000637:Transaminases; C417083:peginterferon alfa-2b